The Effects of Cannabinoids on Individuals with Chronic Pain:
A Critically Appraised Topic

Clinical Scenario

As of 2020, cannabis has been legalized for medicinal purposes in
33 states and the District of Columbia1. The most common reason for
the use of medicinal cannabis treatments is chronic pain1,2. Within the
cannabis plant there are two main components; delta-9tetrahydrocannabinol (THC) and cannabidiol (CBD). Because of the
analgesic and anti-inflammatory effects of cannabinoids and the fight
against the opioid epidemic, there has been an increase in research of
the effects of THC and CBD on patients experiencing chronic
pain1,2,3As the growth of this treatment method continues to increase,
the need for more data and research becomes more crucial. There
needs to be more conclusive evidence either for or against the use of
cannabis treatments to have any serious clinical applications2,4.
Therefore, there was a need to critically appraise the literature
regarding the effects of cannabinoids and/or cannabis on chronic pain.
In doing this, important insight into the use of this treatment in clinical
practice for patients suffering from chronic pain may be found.
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Results

•The literature search resulted in 249 studies: four studies met the inclusion and
exclusion criteria (Table 1).
•In the four studies that met criteria, cannabinoids were used to treat chronic pain
due to pancreatitis1, fibromyalgia2, diabetes or complex regional pain syndrome3,
sickle cell disease4.
•In all four studies, a variation of a Visual Analog Scale was used at baseline and
following intervention to determine the presence and severity of pain1,2,3,4.
•The PEDro scores were determined by the authors of the CAT. Two of the articles
scored an 8/112,4, and two of the articles scored a 10/101,3.
•Three of the studies concluded no significant difference between cannabinoids and
a placebo in chronic pain reduction1,2,4. One study concluded that low doses with a
specific type of inhaler result in chronic pain reduction3.

Discussion and Future Research

Although high-quality studies, there was no conclusive evidence to show that cannabinoids
and/or cannabis are effective in producing analgesic effects in individuals suffering from
chronic pain. Based on the inconclusiveness of the selected studies, determining the
effectiveness of cannabis and/or cannabinoids on chronic pain cannot be achieved. Further
studies involving larger patient populations over a longer period of time need to be performed.
Additionally, if athletic trainers intend to apply this into clinical practice, it is necessary to
determine methodology that can easily be applied in the clinic. These studies should expand to
include patients suffering from chronic musculoskeletal pain with no underlying cause. Future
studies should also focus on the appropriate dosage, variety of cannabis, and means of
administration to determine the most effective intervention for analgesic effects. Based on the
findings of the researchers, it appears that there is not substantial evidence at this time to
justify the use of cannabinoids and/or cannabis in the treatment of chronic pain. Future studies
should be done to continue to explore this topic prior to its implementation in clinical practice.

Clinical Question

Does the use of cannabinoids reduce pain levels in patients
who suffer from chronic, non-cancer pain?

Methods

Terms Used to Guide Search Strategy
• Population: Adults with chronic non-cancer pain
• Intervention: Cannabinoids or cannabis
• Outcome: Chronic pain levels
Sources of Evidence Searched
CINAHL Plus (EBSCO)
PubMed Central
Inclusion Criteria
Subjects with chronic non-cancer pain
Treatment plan including cannabis and/or cannabinoids
Published in the last five years (2016-2021)
Randomized controlled trials
Pain was the outcome measure
Subjects 18 and older
Exclusion Criteria
Studies that used minors as participants
Studies concerning chronic pain due to cancer
Studies that were not randomized controlled trials
Studies that did not involve cannabinoid or cannabis intervention
Articles older than 2016
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